Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) [Yahoo! Finance]
Emergent BioSolutions Inc. (EBS)
Last emergent biosolutions inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs. Was this helpful? Yes No What is Emergent BioSolutions' anthrax franchise and what products does it include? Emergent's anthrax franchise includes the CYFENDUS vaccine, as well as two treatments, Anthrasil [Anthrax Immune Globulin Intravenous (Human)], a polyclonal antibody therapeutic, and raxibacumab, a monoclonal antibody therapeutic, in addition to the BioThrax vaccine. Was this helpful? Yes No What is the significance of this contract award for Emergent BioSolutions and public health preparedness? This procurement award further bolsters anthrax preparedness and demonstrates Emergent's commitment to public health preparedness, according to Paul Williams, senior vice president, products head at
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent BioSolutions Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent BioSolutions Inc. (NYSE: EBS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)GlobeNewswire
- Emergent BioSolutions Inc. (NYSE: EBS) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Why Emergent BioSciences Stock Plummeted Today [Yahoo! Finance]Yahoo! Finance
- 2-Day Virtual Aseptic Processing of Pharmaceutical and Biotech Products Course [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 11/6/24 - Beat
EBS
Sec Filings
- 12/17/24 - Form 4
- 12/10/24 - Form 4
- 12/5/24 - Form EFFECT
- EBS's page on the SEC website